

Dyck¹¹ 27% 가 dying back Said¹² 가¹³

mV/division filter 2~10000 Hz, sweep speed 5 msec/division, sensitivity 5 mV/division

가¹⁴ 가

3. Viking Select (Nicolet Instruments, Biomedical Division, Madison, WI, USA)

가 가 가

16-18 0.1 msec square wave pulses가 4.7 Hz

가 가

3.1 Hz wave pulse가 512~1024 2

1. 2003 2 5 가 30

Erb's point (EN1), C5 (CN2), (N1) L3 (LN1) T12 (TN1) (P1) EN1, CN2, N1 LN1, TN1, P1 가

가 2 mg/dL 30 20

4. SPSS 11.0 for windows

11 9 60.7±9.5 163.2±6.2 cm 11.6±8.8

paired t-test Wilcoxon signed rank test

2. 31 Viking Select (Nicolet Instruments, Biomedical Division, Madison, WI, USA)

Table 1 Table 2 20 10 (50%), 40 10 (25%)

Oh's method 0.1 msec square wave pulse filter 20~3000 Hz, sweep speed 1 msec/division, sensitivity 5

Table 1. Comparison between Distal and Proximal Stimulation of Median Nerve Somatosensory Evoked Potential (n=20).

Patient	Sex /Age	NCS	MNSEP											
			EN1	CN2	N1	EN1- CN2	CN2- N1	EN1- N1	EN1 '	CN2 '	N1 '	EN1 '- CN2 '	CN2 '- N1 '	EN1 '- N1 '
1	F/62	SMP	8.4	12.3	18.1	3.9	5.76	9.66	5.34	9.48	14.8	4.14	5.34	9.34
2	F/65	SMP	11.3	15.2	21.8	3.84	6.6	10.4	6.24	10.2	16.72	3.96	6.52	10.48
3	F/60	SMP	8.82	12.6	18.1	3.78	5.46	9.24	5.58	9.78	14.8	4.2	5.04	9.24
4	M/65	SMP	10.6	15.2	20.5	4.56	5.34	9.9	6.42	11.0	16.4	4.56	5.4	9.96
5	M/70	SMP	9.36	14.0	19.3	4.62	5.34	9.96	5.94	10.1	15.6	4.14	5.52	9.66
6	M/62	SMP	11.5	15.3	21.3	3.78	6.0	9.78	6.72	11.4	16.7	4.68	5.34	10.0
7	M/71	SMP	8.4	12.5	17.6	4.08	5.16	9.24	5.04	9.36	14.8	4.32	5.46	9.78
8	F/54	SMP	8.46	12.6	17.9	4.14	5.28	9.42	5.16	9.72	15.5	4.56	5.82	10.4
9	F/63	SMP	10.7	14.4	19.4	3.66	5.04	8.7	6.66	10.9	16.3	4.2	5.4	9.6
10	F/42	SMP	10.5	14.5	21.1	3.96	6.66	10.6	6.24	10.6	17.5	4.38	6.9	11.3
11	F/76	SMP	9.66	12.8	19.2	3.12	6.42	9.54	6.3	9.84	17.0	3.54	7.16	10.7
12	F/66	SMP	10.4	14.1	20.3	3.72	6.24	9.96	6.24	10.4	16.7	4.2	6.3	10.5
13	M/63	SMP	9.54	13.6	19.4	4.08	5.82	9.9	5.88	10.2	16.1	4.32	5.94	10.3
14	M/61	SMP	10.3	14.2	20.1	3.96	5.88	9.84	6.36	10.5	15.8	4.14	5.3	9.44
15	M/44	SMP	9.9	13.7	19.6	3.84	5.82	9.66	5.52	9.6	15.3	4.08	5.7	9.78
16	M/69	SMP	11.6	14.8	21.1	3.18	6.3	9.48	7.02	11.4	17.5	4.38	6.12	10.5
17	M/50	SMP	no	no	23.6	no	no	no	7.56	12.5	18.8	4.98	6.3	11.3
18	M/55	SMP	9.96	13.7	19.6	3.78	5.88	9.66	6.12	10.1	16.1	3.96	6.06	10.0
19	M/46	SMP	10.7	14.6	20.8	3.9	6.18	10.1	5.82	10.1	16.7	4.32	6.6	10.9
20	F/70	SMP	9.24	12.6	18.7	3.36	6.06	9.42	5.64	9.6	14.9	3.96	5.28	9.24
Mean			9.97	13.83	19.88	3.86	5.85	9.71	6.09	10.34	16.20	4.25	5.88	10.12
± SD			± 1.01	± 1.01	± 1.49	± 0.38	± 0.48	± 0.43	± 0.79	± 0.79	± 1.06	± 0.31	± 0.60	± 0.63

SMP, sensorimotor polyneuropathy

EN1, CN2, and N1 are potentials evoked after the stimulation at the wrist.

EN1 ', CN2 ', and N1 ' are potentials evoked after the stimulation at the antecubital fossa.





Figure 1. The Difference of Waves Elicited by Distal Stimulation (A) and by Proximal Stimulation (B) in Somatosensory Evoked Potential Tests. Note the prominence of waves in (B).

가 9 LN1
7 TN1 P1 3 4
EN1 CN2 가 가 가 P1 (Fig. 1). 9
(peripheral 2 가
conduction defect) 1 가
9 , 1 가 가
가 , 11 3 가
LN1 TN1 P1

Table 2. Comparison between Distal and Proximal Stimulation of Posterior Tibial Nerve Somatosensory Evoked Potential (n=20).

Patient	Sex/Age	NCS	PTSEP									
			LN1	TN1	P1	LN1-P1	TN1-P1	LN1'	TN1'	P1'	LN1'-P1'	TN1'-P1'
1	F/62	SMP	no	no	43.9	no	no	15.7	16.0	39.0	23.3	23.0
2	F/65	NP	no	no	52.0	no	no	11.4	11.9	32.9	21.5	21.0
3	F/60	SMP	no	no	39.0	no	no	13.0	13.3	26.6	13.6	13.3
4	M/65	NP	no	no	no	no	no	13.2	13.9	30.5	16.6	17.4
5	M/70	NP	no	no	42.4	no	no	12.2	12.5	36.1	23.9	23.6
6	M/62	SMP	no	no	no	no	no	11.5	12.0	30.6	19.1	18.6
7	M/71	NP	no	no	42.8	no	no	11.3	11.5	31.8	20.5	20.3
8	F/54	SMP	no	no	38.1	no	no	11.3	11.5	31.8	20.5	20.3
9	F/63	NP	no	no	38.7	no	no	13.4	13.5	26.0	12.6	12.5
10	F/42	NP	no	no	47.3	no	no	no	no	43.2	no	no
11	F/76	SMP	21.2	21.8	38.8	17.6	17	16.2	16.6	33.0	16.8	16.4
12	F/66	NP	no	no	47.7	no	no	no	no	29.7	no	no
13	M/63	SMP	21.2	21.6	40.9	19.7	19.3	12.1	12.6	37.6	25.5	25.0
14	M/61	SMP	24.5	25.0	41.8	17.3	16.5	14.3	14.8	33.2	18.9	18.4
15	M/44	SMP	23.7	25.6	42.8	19.1	17.2	16.8	16.9	40.7	23.9	23.8
16	M/69	NP	no	no	51.0	no	no	no	no	43.2	no	no
17	M/50	NP	no	no								
18	M/55	SMP	21.4	21.9	40.5	19.1	18.6	13.5	14.8	32.6	19.1	17.8
19	M/46	SMP	no	no								
20	F/70	SMP	no	no								
Mean			22.40	23.18	43.18	18.56	17.72	13.28	13.70	34.03	19.70	19.39
± SD			± 1.58	± 1.95	± 4.43	± 1.05	± 1.18	± 1.86	± 1.86	± 5.20	± 3.86	± 3.80

SMP, sensorimotor polyneuropathy; NP, no potential in sural nerve
 LN1 and TN1, and P1 are potentials from the stimulation at the ankle.
 LN1' and TN1', and P1' are potentials from the stimulation at the popliteal fossa.



REFERENCES

1. Chiappa KH. Evoked potentials in clinical medicine. 3rd ed. New York, Lippincott-Raven. 1997;509-528.
2. Halar EM, Graf RJ, Halten JB, Brozovich FV, Soine TL. Diabetic neuropathy: A clinical, laboratory and electrodiagnostic study. *Arch Phys Med Rehabil* 1982;63:298-303.
3. Olsson Y, Sourander P, Angervail L. A pathoanatomical study of the central and peripheral nervous system in diabetes of early onset and long duration. *Patho Europ* 1968;3:62-79.
4. Behse F, Buchthal F, Carlsen F. Nerve biopsy and conduction studies in diabetic neuropathy. *J Neurol Neurosurg Psychiat* 1977;40:1072-1082.
5. Park YS, Lee HK, Koh CS, et al. Prevalence of diabetes mellitus and IGT in Yonchon County, Korea. *Diabetes Care* 1995;18:534-538.
6. Shin CS, Lee HK, Koh CS, et al. Risk factors for the development of NIDDM in Yonchon County, Korea. *Diabetes Care* 1997;20:1842-1846.
7. Suzuki C, Ozaki I, Tanosaki M, Suda T, Baba M, Matsunaga M. Peripheral and central conduction abnormalities in diabetes mellitus. *Neurology* 2000;54:1932-1937.
8. Bartolomei L, Lelli S, Negrin P. Somato-sensory evoked potentials in diabetes type I. *Electromyogr Clin Neurophysiol* 1991;31:43-46.
9. Simmons Z, Feldman EL. Update on diabetic neuropathy. *Curr Opin Neurol* 2002;15:595-603.
10. Dyck PJ, Thomas PK, Asbury AK, Winegard AI, Porte D. Diabetic neuropathy. 1st ed. Philadelphia, Saunders. 1987;41.
11. Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort. *Neurology* 1993;43:817-24.
12. Thomas PK. Diabetic neuropathy: mechanisms and future treatment options. *J Neurol Neurosurg Psychiat* 1999; 67:277-279.
13. Said G, Slama G, Selva J. Progressive centripetal degeneration of axons in small fibre diabetic neuropathy. *Brain* 1983;106:791-807.
14. Dyck PJ, Karnes JL, O'Brien P, Okazaki H, Lais A, Engelstad J. The spatial distribution of fiber loss in diabetic polyneuropathy suggests ischaemia. *Ann Neurol* 1986; 19:440-449.
15. Oh SJ. Normal values for common nerve conduction tests. In: Oh SJ et al., eds. *Clinical electromyography - nerve conduction studies*. 2nd ed. Baltimore, Williams & Wilkins. 1993;84-104.
16. Chiappa KH, Ropper AH. Evoked potentials in clinical medicine. *N Engl J Med* 1982;306:1140-1150.
17. American Electroencephalographic Society. Guidelines for clinical evoked potential studies. *J Clin Neurophysiol*

- 1984;1:3-53.
18. Aminoff MJ. Evoked potentials in clinical medicine. *Q J Med* 1986;228:345-362.
 19. Palma V, Serra LL, Armentano V, Serra FP, Nolfi G.. Somatosensory evoked potentials in non-insulin-dependent diabetics with different degrees of neuropathy. *Diabetes Res Clin Pract* 1994;25:91-96.
 20. Parry GJ, Aminoff MJ. Somatosensory evoked potentials in chronic acquired demyelinating peripheral neuropathy. *Neurology* 1987;37:313-316.
 21. Eisen A, Purves S, Hoirch M. Central nervous system amplification: its potential in the diagnosis of early multiple sclerosis. *Neurology* 1982;32:359-364.
 22. Nakamura R, Noritake M, Hosoda Y, Kamakura K, Nagata N, Shibasaki H. Somatosensory conduction delay in central and peripheral nervous system of diabetic patients. *Diabetes Care* 1992;15:532-535.
 23. Baba M, Ozaki I. Electrophysiological changes in diabetic neuropathy: from subclinical alterations to disabling abnormalities. *Arch Physiol Biochem* 2001;109:234-240.